Gossamer Bio’s Post

First aXess Pivotal Trial Cases in Spain   Last week, a team led by Prof. Dr. Gaspar Mestres completed the first implantations of the aXess vascular access conduit in Spain, at the Hospital Clínic de Barcelona, as part of the ongoing aXess pivotal trial.   The aXess pivotal study is evaluating the safety and efficacy of the Xeltis hemodialysis access conduit in patients with end-stage renal disease. The aXess conduit is gradually replaced by the patients’ own living healthy tissue through a therapeutic process called Endogenous Tissue Restoration (ETR).   Find out more about the trial here: https://axesspivotal.com/ #Xeltis #Trial #CardiovascularHealth #MedTech #ClinicalDevelopment

IFPMA, IGBA - International Generic and Biosimilar medicines Association, Global Diagnostic Imaging, Healthcare IT, and Radiation Therapy Trade Association (#DITTA), Global Self-Care Federation, World Hypertension League, and PATH submitted a constituency statement to the World Health Assembly (#WHA) welcoming the WHO’s continued commitment to non-communicable diseases (NCDs).   A life-course approach to tackling NCDs is critical given the unsustainable pressures the rising burden of chronic conditions and co-morbidities are placing on healthcare systems worldwide. We remain committed to working with others to build access solutions and contribute toward stronger health systems to improve the lives of people living with NCDs.   👇Read our statement: https://ifpma.info/4dZCei2

🔊 Coming up soon! 🌏 The 7th edition of the World Symposium on Pulmonary Hypertension is being held on June 29-30/July 1, 2024, in Barcelona, Spain. The WSPH is the most important scientific event in the field of pulmonary hypertension. It has been convened every five years since the Evian edition in 1998 (including Venice 2003, Dana Point 2008, Nice 2013, and Nice 2018). 🔹 Very honoured to be a member of Task Force n°1, on Patient Perspectives, together with patients and patient representatives Hall Skaara Gergely Meszaros JD, MSc and Colleen Brunetti, M.Ed, C.H.C., alongside professors Adam Torbicki H. James Ford MD and Simon Gibbs! 🔹 The WSPHs serve as a cornerstone for advancing pulmonary hypertension science and charting pathways for future progress. The published supplements, featuring symposia proceedings, represent a compendium of articles widely recognized and frequently cited within this scientific domain. 🔹 With each successive iteration of the WSPH there has been a notable increase in attendance, reflecting the escalating interest among stakeholders in this field. The 6th edition in Nice 2018 attracted more than 1.500 attendees. 🔹 This year the task force on patient perspectives will be the first to report back on its findings (we have been working on our paper for over a year!), on the opening day! 🔹 The Alliance for Pulmonary Hypertension, of which I am Secretary General, will be present with a booth and the representatives of a few of its member associations. 🔹 I look forward to this extraordinary opportunity to meet, learn, share and network with members of the wider pulmonary hypertension community. Read more at: https://wsph2024.com/ #pulmonaryhypertension #pulmonaryarterialhypertension #PAH #chronicthromboembolicpulmonaryhypertension #CTEPH #knowledgesharing #knowledgeexchange #patientempowerment #patienteducation #allianceforph #organtransplant #organdonation #transplant #lungtransplant

#ESHAL2024 #ESHCONFERENCES Day 2 of the 4th How to Diagnose & Treat ACUTE #LEUKEMIAS conference starts with 3 parallel Meet-the-expert sessions. Dr. med. Nicola Gökbuget, head of the German Multicenter Study Group for Adult ALL (#GMALL) and the head of Clinical trial center of University Hospital Frankfurt had a lively discussion with international peers on the optimal use of Asparaginase in adults with ALL.  One key point was to identify patients who are at high risk of severe liver toxicities (e.g. age, BMI>30, steatosis hepatis) before induction therapy and reduce dose in order to reduce risk of toxicities and interruptions. Guidelines on how to reduce and handle peg-asparaginase should be available in hospitals and strive for peg-asparaginase activity measurements.  Chairs: Hervé Dombret, Gert Ossenkoppele, Christoph Röllig, Wendy Stock #leusm #ESHELEARNING

📍Video #15 Pulmonary Embolism (PE) - As per American Lung Association, ALA 2023: Pulmonary embolism can be life-threatening with 10-30% of individuals dying within one month of diagnosis.. Pulmonary embolism affects around 900,000 people in the U.S. every year - Most pulmonary embolism is caused by blood clots in the legs (deep vein thrombosis. DVT). ————————————————————— Part of the right and fast managment is to have Pulmonary Embolism Response Teams (PERT) in our hospitals 🏥 . This following study by T.D. Bui. It Emphasis the importance of having Pulmonary embolism response teams (PERTs) for the evaluation and treatment of patients with acute PE to improve the efficiency of PE care in developing country’s hospitals. https://lnkd.in/eR6qssUS. T D Bui et al. Clin Ter. 2023 Nov-Dec - At the end of this study, let’s all support establishing PERTeam in our facilities 🏥.

🔍 For a #COPD patient, having pulmonary hypertension is associated with significantly worse survival. By measuring the volume of small pulmonary vessels using quantitative CT, physicians may one day be able to identify those patients at greatest risk. In our study, conducted in collaboration with Dr. Hector Cajigas of the Mayo Clinic, we found that for patients with PH-COPD, reduced small vessel volume was associated with an 8-fold increased risk of death. 👉🏻 Read the full story in our recent manuscript published in Pulmonary Circulation: https://lnkd.in/eHp-UySq

Real-world walking cadence should be further considered as a prognostic marker of COPD in observational research and in drug and non-drug clinical trials, as well as while developing pulmonary rehabilitation and physical activity interventions https://bit.ly/3TfJezh

What a week! Thanks to #hjartlungfonden and #regionskane I now have guaranteed funds to continue my research for the next 5 years! My research involves among other things: - To study how cardiac rehabilitation (CR) in Sweden is organized and identify which components of CR most effectively help patients to reach treatment goals. - To evaluate whether a) monitoring CR structure and processes on center-level through the #SWEDEHEART registry and b) providing active on-site implementation support can improve guideline adherence at Swedish CR centers - To implement tools to increase early initiation of combination lipid-lowering therapy for ACS patients and evaluate the effect on LDL-C levels and prognosis. - To evaluate how structured follow-up of glucose disturbances within CR can improve identification and treatment of diabetes. I am grateful for the trust #hjartlungfonden and #regionskane have shown so I can continue this work together with all my great fellow secondary prevention researchers around the country <3   

𝗣𝗮𝘁𝗶𝗲𝗻𝘁 𝗽𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲 𝗺𝗮𝘁𝘁𝗲𝗿𝘀! 👈 It is well established that pulmonary hypertension (PH) places a substantial burden on patients' health-related quality of life (HRQoL). As more effective treatments have been developed for this condition, evaluating treatment benefit based on experiences reported by patients regarding their well-being and physical, social, economic and emotional functioning has increased. Patient perspective matters and it should be a mold for every initiative in the field of PH research, diagnosis and treatment. How you feel should determine the future of PH research and treatment. The importance of patient associations in this regard is becoming more prominent. ➡Find out more about PROMs: https://lnkd.in/ecD2Q6Na ➡Read more abut PHA Europe’s initiative: phaeurope.org 🔎Join our premier virtual platform for PH patients and stakeholders, an online place that connects hearts and empowers minds: belaircenter.info #pulmonaryhypertension #patientcare #accesstocare #awareness #patientempowerment #patientliteracy #PROMs #HRQoL #PAH #CTEPH #research #medicine

We are thrilled to invite you to the 16th International Conference on COPD, set to take place in the stunning city of Paris, France. This premier event will gather global experts, researchers, and healthcare professionals to explore the latest advancements in COPD research and management. What to Expect: Keynote Presentations: Gain insights from leading experts as they share groundbreaking research and future directions in COPD. Interactive Workshops: Engage in hands-on sessions focused on innovative treatment strategies and practical applications. Panel Discussions: Join discussions on global perspectives and challenges in COPD management. Networking Opportunities: Connect with peers and industry leaders to exchange ideas and build valuable collaborations. Exhibition: Discover cutting-edge technologies and solutions from top companies in the field. For More Info: https://cutt.ly/Qekv9n6K Save the dates and stay tuned for updates on speakers and program details! #COPD #RespiratoryMedicine #HealthcareConference #MedicalResearch #COPD2024 #ParisConference #COPDTherapeutics #COPDExacerbations #Lungcancer #CardiovascularDiseases #PulmonaryHypertension #COPDComplications